Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year,

Size: px
Start display at page:

Download "Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year,"

Transcription

1 ASTHMA CHART 1 Optum Research Database Proportion of asthma patients with prescription fills for rescue and controller medications by year, Controller medication 1 Rescue medication No controller or rescue medication In 215, 44.4% of asthma patients had a controller medication prescription fill and 65.9% had a fill for a rescue medication. Results were similar in 216. More than a quarter of patients diagnosed with asthma did not have any asthma-related medication fills in each year. 1. At least one asthma diagnosis in any position; and A total of 65,751 and 91,214 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple rescue medication classes.

2 ASTHMA CHART 2 Optum Research Database Proportion of asthma patients with prescription fills for controller medications classes by year, ICS ICS/LABA LABA LAMA LM MAST METH MONOC No controller medication The most commonly filled controller medications were fixed dose ICS/ LABA followed by LM, ICS and LAMA. More than half of asthma patients did not have any asthma-related controller medication fills in each year. ICS inhaled corticosteroid; LABA long-acting beta agonist; LAMA long-acting muscarinic antagonist; LM leukotriene modifiers; MAST mast cell stabilizers; METH methylxanthines MONOC monoclonal antibodies (IL-5 inhibitors, anti-ige) 1. At least one asthma diagnosis in any position; and A total of 65,751 and 91,214 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple controller medication classes.

3 ASTHMA CHART 3 Optum Research Database Proportion of asthma patients with prescription fills for rescue medications classes by year, OCS SABA SAMA SAMA/SABA No rescue medication Among patients diagnosed with asthma, 52.5% and 48.1% had at least one pharmacy fill for a SABA medication in 215 and 216, respectively. More than one-third of asthma patients had at least one pharmacy fill for an OCS in each year, and more than one-third did not have any pharmacy fills for rescue medications. OCS systemic corticosteroids; SABA short-acting beta agonist SAMA short-acting muscarinic antagonist 1. At least one asthma diagnosis in any position; and A total of 65,751 and 91,214 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple rescue medication classes.

4 COPD CHART 4 Optum Research Database Proportion of COPD patients with prescription fills for rescue and controller medications by year, Controller medication 1 Rescue medication No controller or rescue medication In 215, 34.3% of COPD patients had a controller medication prescription fill and 54.6% had a fill for a rescue medication. Results were similar in 216. More than a third of patients diagnosed with COPD did not have any COPD-related medication fills in each year. 1. At least one COPD diagnosis in any position; and A total of 354,2 and 446,85 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for controller and rescue medications.

5 COPD CHART 5 Optum Research Database Proportion of COPD patients with prescription fills for controller medication classes by year, ICS ICS/LABA LABA LAMA LAMA/LABA METH PDE No controller medication Among enrollees diagnosed with COPD, the most commonly filled class of controller medication was an ICS/LABA followed by LAMA. In each year, nearly one quarter of COPD patients had pharmacy fills for an ICS/LABA and roughly 15% of COPD patients had at least one pharmacy fill for a LAMA. ICS inhaled corticosteroid; LABA long-acting beta agonist LAMA long-acting muscarinic antagonist; METH methylxanthines; PDE phosphodiesterase-4 inhibitors Approximately 65% of COPD patients did not have any pharmacy fills for controller medications in 215 or At least one COPD diagnosis in any position; and A total of 354,2 and 446,85 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple controller medication classes.

6 COPD CHART 6 Optum Research Database Proportion of COPD patients with prescription fills for rescue medication classes by year, OCS SABA SAMA SAMA/SABA No rescue medication Among enrollees diagnosed with COPD, 36.8% and 38.4% had at least one pharmacy fill for a SABA medication in 215 and 216, respectively. Approximately 35% of COPD patients had at least one pharmacy fill for an OCS in each year. In 215 and 216, respectively, 45.4% and 43.4% of COPD patients did not have any pharmacy fills for rescue medications. OCS systemic corticosteroids; SABA short-acting beta agonist; SAMA short-acting muscarinic antagonist 1. At least one COPD diagnosis in any position; and A total of 354,2 and 446,85 enrollees met the above criteria in 215 and 216, respectively. The increase in patient counts from 215 to 216 is due in part to the change from ICD-9 to ICD-1. The percentages in the graph do not sum to 1% because some patients filled prescriptions for multiple rescue medication classes. WF51132

Disclosure Statement. Epidemiological Data

Disclosure Statement. Epidemiological Data EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov

More information

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE A F O C A l p O I N T l E A r N I N g p r O g r A m m E CHRONIC OBSTRUCTIVE PULMONARY DISEASE S E C O N D E D I T I O N BOOK 1 September 2013 FP120/1 CENTRE FOR PHARMACY POSTGRADUATE EDUCATION About CPPE

More information

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

THE COPD PRESCRIBING TOOL

THE COPD PRESCRIBING TOOL THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their

More information

Global Initiative for Asthma (GINA) What s new in GINA 2015?

Global Initiative for Asthma (GINA) What s new in GINA 2015? Global Initiative for Asthma (GINA) What s new in GINA 2015? GINA Global Strategy for Asthma Management and Prevention What s new in GINA 2015 (1) Add-on tiotropium by soft-mist inhaler is a new other

More information

2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017

2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain

More information

Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care

Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care Asthma Population Management: Identifying Persistent Asthma, Defining High Risk Asthma, and Measuring Quality of Asthma Care Michael Schatz, MD, MS Allergy Department Kaiser Permanente, San Diego, CA Constructs

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64)

2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64) 2014 Physician Quality Reporting System Data Collection Form: Asthma (for patients aged 5-64) Physician Name: Patient Name: Last First MI Date of Birth: / / mm dd yyyy Gender: M F Patient Insured - Traditional

More information

Global Initiative for Asthma (GINA) What s new in GINA 2017?

Global Initiative for Asthma (GINA) What s new in GINA 2017? Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome

More information

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark

Treatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting

More information

Long Term Care Formulary RS -29

Long Term Care Formulary RS -29 RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For

More information

April 10 th, Bond Street, Toronto ON, M5B 1W8

April 10 th, Bond Street, Toronto ON, M5B 1W8 Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond

More information

2. Does the patient have chronic urticaria? Y N

2. Does the patient have chronic urticaria? Y N Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Xolair (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Section II: Detailed Measure Specifications

Section II: Detailed Measure Specifications Section II: Detailed Measure Specifications Provide sufficient detail to describe how a measure would be calculated from the recommended data sources, uploading a separate document (+ Upload attachment)

More information

COPD Update. Muhammad Talha Khan MD. COPD Exacerbations. COPD Clinical Importance. COPD Pathophysiology. Overview/Objectives

COPD Update. Muhammad Talha Khan MD. COPD Exacerbations. COPD Clinical Importance. COPD Pathophysiology. Overview/Objectives Overview/Objectives COPD Update Muhammad Talha Khan MD Pulmonologist St Croix Regional Medical Center, St Croix Falls, WI. Overview of COPD and disease impact Classification of COPD Severity Treatment

More information

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

A Study of Prescription Pattern in the Management of COPD in a Tertiary Care Hospital.

A Study of Prescription Pattern in the Management of COPD in a Tertiary Care Hospital. DOI: 10.21276/aimdr.2016.2.3.39 Original Article ISSN (O):2395-2822; ISSN (P):2395-2814 A Study of Prescription Pattern in the Management of COPD in a Tertiary Care Hospital. Mazher Maqusood 1, Farhan

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)

Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

A multitude of devices

A multitude of devices A multitude of devices Dr Andrew Scroop Respiratory Consultants 15 th September 2018 STEPWISE PHARMACOLOGICAL MANAGEMENT OF STABLE COPD COPD Inhalers MILD FEV 1 60 80% predicted few symptoms breathless

More information

Doctor of Medicine. Alastair Stewart Dept. of Pharmacology 8 th Floor, Medical Building Rm. N802

Doctor of Medicine. Alastair Stewart Dept. of Pharmacology 8 th Floor, Medical Building Rm. N802 Doctor of Medicine Alastair Stewart Dept. of Pharmacology 8 th Floor, Medical Building Rm. N802 astew@unimelb.edu.au Drugs affecting airway structure and function 2 Objectives Understand and know the mechanism

More information

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA

PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation

More information

Update on Pulmonary Diseases. Jeffrey Lessar, MD

Update on Pulmonary Diseases. Jeffrey Lessar, MD Update on Pulmonary Diseases Jeffrey Lessar, MD 1 No disclosures to make No conflicts 2 Goals Update on key changes in Pulmonary Therapy 3 Spirometry Spirometry FEV1- forced expiratory Volume in 1 Sec

More information

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital

Asthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and

More information

Wirral COPD Prescribing Guidelines

Wirral COPD Prescribing Guidelines Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed

More information

COPD: Current Medical Therapy

COPD: Current Medical Therapy COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary

Three s Company - The role of triple therapy in chronic obstructive pulmonary Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov

More information

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017

Algorithm for the use of inhaled therapies in COPD Version 2 May 2017 Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments

More information

New Therapies for Asthma

New Therapies for Asthma New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the

More information

Design - Multicentre prospective cohort study. Setting UK Community Pharmacies within one CCG area within the UK

Design - Multicentre prospective cohort study. Setting UK Community Pharmacies within one CCG area within the UK Enabling Patient Health Improvements through COPD (EPIC) Medicines Optimisation within Community Pharmacy: a prospective cohort study Abstract Objectives To improve patients ability to manage their own

More information

LAMA Products for the Treatment of COPD

LAMA Products for the Treatment of COPD FINAL REPORT LAMA Products for the Treatment of COPD Pharmacoepidemiology Unit: Censored Final Report Tara Gomes, Andrea Gershon, Matthew Stanbrook, Ximena Camacho, Diana Martins, Samantha Singh, Zhan

More information

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11/11 Last Review Date: 08/17 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory

More information

«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients»

«Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients» «Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients» Baseline data from a randomized controlled trial 5 th Swiss Health Services Research Symposium,

More information

Current Approaches to Asthma & COPD

Current Approaches to Asthma & COPD 10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:

More information

requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group

requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.

More information

GSK Medicine: salmeterol, Salmeterol+Fluticasone proprionate, fluticasone propionate, beclomethasone

GSK Medicine: salmeterol, Salmeterol+Fluticasone proprionate, fluticasone propionate, beclomethasone GSK Medicine: salmeterol, Salmeterol+Fluticasone proprionate, fluticasone propionate, beclomethasone Study No.: WWE111984/WEUSRTP2640/EPI40528 Title: The Asthma Death Case Control Study (ADCCS): Association

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.

More information

Class Update: Asthma / COPD Medications

Class Update: Asthma / COPD Medications Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find

More information

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Altarum Bridges to Excellence 3520 Green Court, Suite 300 Ann Arbor, MI 48105 bte@altarum.org www.bridgestoexcellence.org

More information

AND COPD ADVANCES IN COMBINATION THERAPY FOR ASTHMA. Jan Lotvall. Editor. Krefting Research Centre, University of Gothenburg,

AND COPD ADVANCES IN COMBINATION THERAPY FOR ASTHMA. Jan Lotvall. Editor. Krefting Research Centre, University of Gothenburg, ADVANCES IN COMBINATION THERAPY FOR ASTHMA AND COPD Editor Jan Lotvall Krefting Research Centre, University of Gothenburg, Sweden A Wiley Sons, Ltd., Publication Contents Contributors xi Preface 1 Similarities

More information

New TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator

New TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator New TLD Indication: Asthma RELIEF-1 Study Nick ten Hacken, MD Study Co-Principal Investigator The Burden of Asthma WW Adult Asthma Prevalence 230.5 Million Mild/Intermittent 161.9 Million (70%) Moderate

More information

Biologic Agents in the treatment of Severe Asthma

Biologic Agents in the treatment of Severe Asthma Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human

More information

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA

SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS

More information

Algorithm for the use of inhaled therapies in COPD

Algorithm for the use of inhaled therapies in COPD Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed

More information

David M Kern 1*, Jill Davis 2, Setareh A Williams 3, Ozgur Tunceli 1, Bingcao Wu 1, Sally Hollis 4, Charlie Strange 5 and Frank Trudo 2

David M Kern 1*, Jill Davis 2, Setareh A Williams 3, Ozgur Tunceli 1, Bingcao Wu 1, Sally Hollis 4, Charlie Strange 5 and Frank Trudo 2 Kern et al. Respiratory Research (2015) 16:52 DOI 10.1186/s12931-015-0210-x RESEARCH Open Access Comparative effectiveness of budesonide/ formoterol combination and fluticasone/ salmeterol combination

More information

What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals

What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals Asthma is an inflammatory disease Relaxed smooth muscles Air trapped in alveoli Tightened

More information

Evaluation of Asthma Management in Middle EAst North Africa Adult population

Evaluation of Asthma Management in Middle EAst North Africa Adult population STUDY REPORT SUMMARY Evaluation of Asthma Management in Middle EAst North Africa Adult population Descriptive study on the management of asthma in an asthmatic Middle East Africa adult population Background/Rationale:

More information

Revefenacin (TD-4208) Phase 3 Efficacy Results

Revefenacin (TD-4208) Phase 3 Efficacy Results Revefenacin (TD-4208) Phase 3 Efficacy Results Once-daily, Nebulized Long-Acting Muscarinic Antagonist (LAMA) October 20, 2016 THERAVANCE, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered

More information

Using Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease

Using Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease RESEARCH ARTICLE Using Big Data to Assess Prescribing Patterns in Greece: The Case of Chronic Obstructive Pulmonary Disease Kyriakos Souliotis 1,2 *, Chara Kani 3, Manto Papageorgiou 4, Dimitrios Lionis

More information

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department

TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing

More information

Changing Landscapes in COPD New Zealand Respiratory Conference

Changing Landscapes in COPD New Zealand Respiratory Conference Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Setting The setting was the community. The economic study was carried out in New Jersey, USA.

Setting The setting was the community. The economic study was carried out in New Jersey, USA. Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy Luskin A, Bukstein D, Kocevar V S, Yin D D Record Status This

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum

Improving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University

More information

Case approach in Asthma and COPD. Assoc.Prof.Sunee Lertsinudom BSc.Grad.Diplo.BCP. Department of Clinical pharmacy Khonkaen University

Case approach in Asthma and COPD. Assoc.Prof.Sunee Lertsinudom BSc.Grad.Diplo.BCP. Department of Clinical pharmacy Khonkaen University Case approach in Asthma and COPD Assoc.Prof.Sunee Lertsinudom BSc.Grad.Diplo.BCP. Department of Clinical pharmacy Khonkaen University Asthma Diagnosis History and patterns of symptoms Physical examination

More information

Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO)

Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO) Version V1.4 Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO) An observational study evaluating the benefits of early intervention with maintenance

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Position within the Organisation

Position within the Organisation ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September

More information

New Drug Evaluation: Olodaterol oral inhalation solution (Striverdi Respimat)

New Drug Evaluation: Olodaterol oral inhalation solution (Striverdi Respimat) Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications

The Acute & Maintenance Treatment of Asthma via Aerosolized Medications The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.

More information

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior

More information

The National Asthma Education and Prevention Program s

The National Asthma Education and Prevention Program s Long-Acting b-agonist Among Children and Adults With Asthma Elizabeth A. Wasilevich, PhD, MPH; Sarah J. Clark, MPH; Lisa M. Cohn, MS; and Kevin J. Dombkowski, DrPH Managed Care & Healthcare Communications,

More information

Prescribing guidelines: Management of COPD in Primary Care

Prescribing guidelines: Management of COPD in Primary Care Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish

More information

RightBreathe to help with inhaler prescribing and technique

RightBreathe to help with inhaler prescribing and technique www.rightbreathe.com RightBreathe to help with inhaler prescribing and technique Dr Azhar Saleem GP Respiratory Lead, Lambeth CCG GP Specialist NHS London Procurement Partnership Clinical Lead RightBreathe

More information

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled

More information

Original Research. Key words: Chronic obstructive pulmonary disease, LAMA, LABA, tiotropium, salmeterol, formoterol

Original Research. Key words: Chronic obstructive pulmonary disease, LAMA, LABA, tiotropium, salmeterol, formoterol Characteristics and Health Care Resource Use of Subjects with COPD in the Year Before Initiating LAMA Monotherapy or LAMA+LABA Combination Therapy: A U.S. Database Study Saurabh Nagar, BPharm, 1* Jeetvan

More information

RESPIRATORY SYSTEM - PHARMACOLOGY-

RESPIRATORY SYSTEM - PHARMACOLOGY- RESPIRATORY SYSTEM - PHARMACOLOGY- PULSE - Mast cell stabilizers : a.have safe profile, so they're recommended for pregnant & children b.they work by blocking IgE receptors on mast cells - There is a case

More information

Asthma COPD Update 2018

Asthma COPD Update 2018 Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State

More information

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?

Changing Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH

More information

News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4

News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4 SPECIAL EDITION: COPD CME AVAILABLE! News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4 Update on Chronic Obstructive Lung Disease (COPD) 2013 During 2013, the Institute for Evidence-Based

More information

Tiotropium: Do the findings of a CV safety signal in the meta-analyses have implications for all drugs to treat COPD?

Tiotropium: Do the findings of a CV safety signal in the meta-analyses have implications for all drugs to treat COPD? Tiotropium: Do the findings of a CV safety signal in the meta-analyses have implications for all drugs to treat COPD? Lorcan McGarvey MD FRCP Queen s University Belfast CSRC Outcomes Think Tank meeting:

More information

DUPIXENT (dupilumab) subcutaneous injection

DUPIXENT (dupilumab) subcutaneous injection DUPIXENT (dupilumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Asthma Treatment Guideline for Adults (aged 17 and over)

Asthma Treatment Guideline for Adults (aged 17 and over) Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version

More information

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing

What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD

More information

Chronic Obstructive Pulmonary Diseases: 2 Novartis Pharmaceuticals Company, East Hanover, New Jersey. 3 KMK Consulting Inc., Florham Park, New Jersey

Chronic Obstructive Pulmonary Diseases: 2 Novartis Pharmaceuticals Company, East Hanover, New Jersey. 3 KMK Consulting Inc., Florham Park, New Jersey 223 GOLD-adherent Prescribing and Resource Utilization Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Original Research Effects of GOLD-Adherent Prescribing on COPD Symptom Burden,

More information

Adherence to asthma controller medication regimens

Adherence to asthma controller medication regimens Respiratory Medicine (2005) 99, 1263 1267 Adherence to asthma controller medication regimens D.A. Stempel a,, S.W. Stoloff b, J.R. Carranza Rosenzweig c, R.H. Stanford c, K.L. Ryskina d, A.P. Legorreta

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

COPD/Asthma. Prudence Twigg, AGNP

COPD/Asthma. Prudence Twigg, AGNP COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased

More information

Evidence Review for Prescribing Clinical Network

Evidence Review for Prescribing Clinical Network Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:

More information

RESPIRATORY CARE IN GENERAL PRACTICE

RESPIRATORY CARE IN GENERAL PRACTICE RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they

More information

CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT. Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board

CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT. Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board CONFLICT OF INTEREST Employee of Auckland District Health

More information

Who can get most benefit

Who can get most benefit Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler

More information

Global Initiative for Asthma (GINA) What s new in GINA 2016?

Global Initiative for Asthma (GINA) What s new in GINA 2016? Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA

#POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA #POMAD8 #ChoosePOMA Where There s Smoke There s Obstruction Stephen G. Basheda, D.O., F.C.C.P. 1 Disclosures Dr. Basheda is an independent contractor for AstraZeneca Pharmaceuticals, LP and GlaxoSmithKline and on the speaker

More information